Safety of monoclonal antibodies for the technician: Myth or reality? about a survey of professional practice;Innocuité des anticorps monoclonaux pour le manipulateur: Mythe ou réaiité? A propos d'une enquête de pratiques professionnelles

Journal de Pharmacie Clinique

Volumn 27, Issue 4, 2008, Pages 227-233

  Pigneret Bernard, S ^a   Saint Lorant, G ^b   Divanon, F ^a  

^a Service de Pharmacie   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

Handling; Monoclonal antibodies; Oncology; Safety

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CONTAMINATION; DIGESTIVE SYSTEM CANCER; DRUG CARCINOGENICITY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; FERTILITY; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MUTAGENICITY; OCCUPATIONAL HAZARD; OCCUPATIONAL SAFETY; PHARMACIST ATTITUDE; PHARMACY TECHNICIAN; PREGNANCY; PROFESSIONAL PRACTICE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SARCOMA; TERATOGENICITY; URINARY TRACT CANCER;

EID: 60749107480     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: 10.1684/jpc.2008.0099     Document Type: Review

References (19)

1. Décret no 2005-1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné á l'article L. 162-22-7 du code de la Sécurité sociale. Journal officiel de la République française du 26 août 2005.
2. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Derm 2002; 47: 312-3.
3. Lucente P, lorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Derm 2000; 43: 172.
4. Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res 2008; 25: 131 8-26.
5. Hill J, Eyles JE, Elvin SJ, Healey GD, Lukaszewski RA, Titball RW. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 2006; 74: 3068-70.
6. Folkesson HG, Weström BR, Karlsson BW. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand 1990; 139: 347-54.
7. Site internet du Vidal. Résumés des caractéristiques du produitde l'Herceptin®. Consulté le 15/04/2008.
8. Site internet du Vidal. Résumés des caractéristiques du produit de l'Avastin®. Consulté le 15/04/2008.
9. Site internet du Vidal. Résumés des caractéristiques du produit du Mabthera®. Consulté le 15/04/2008.
10. Site internet de la FDA. Resumé des caractéristiques du Mylotarg®. http://www.fda.gov/cder/foi/label/2001/21174s2lbl.pdf consulté le 15/04/2008.
11. Miettinen PJ, BergerJE, Meneses J, Phung Y, Pedersen RA, Werb Z, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376: 337-41.
12. Miettinen PJ, Chin JR, Shum L, Slavkin HC, Shuler CF, Derynck R, et al. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat Genet 1999; 22: 69-73.
13. Robinson A, Watson W, Leslie K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Onco/2007; 8: 738-43.
14. Lee S, Schover L, Partridge A, Patrizio P, Wallace W, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-31.
15. Site internet de l'EMEA. Erbitux, European Public assessment report, Scientific discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/ 089404en6.pdf consulté le 15/04/2008.
16. Site internet du Vidal. Résumés des caractéristiques du produit du Mabcampath®. Consulté le 15/04/2008.
17. Focarelli R, Francavilla S, Francavilla F, Delia Giovampaola C, Santucci A, Rosati F. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. Mol Hum Reprod 1999; 5: 46-51.
18. Bandyopadhyay D, Mandal M, Adam A, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent Protein Kinase in Mammalian Cells. J Biol Chem 1998; 273: 1568-73.
19. ICH. Note for Guidance on the need for Carcinogenicity studies of pharmaceuticals (CPMP/ICH/140/95); http://www.emea.europa.eu/pdfs/human/ich/ 014095en.pdf. consulté le 05/03/2008.